A detailed history of Morgan Stanley transactions in Cerus Corp stock. As of the latest transaction made, Morgan Stanley holds 2,012,432 shares of CERS stock, worth $3.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,012,432
Previous 1,400,316 43.71%
Holding current value
$3.6 Million
Previous $3.02 Million 25.76%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

BUY
$1.66 - $2.42 $1.02 Million - $1.48 Million
612,116 Added 43.71%
2,012,432 $3.8 Million
Q4 2023

Feb 13, 2024

BUY
$1.25 - $2.35 $580,651 - $1.09 Million
464,521 Added 49.64%
1,400,316 $3.02 Million
Q3 2023

Nov 15, 2023

BUY
$1.5 - $3.07 $24,103 - $49,331
16,069 Added 1.75%
935,795 $1.52 Million
Q2 2023

Aug 14, 2023

SELL
$1.79 - $2.9 $1.09 Million - $1.76 Million
-608,324 Reduced 39.81%
919,726 $2.26 Million
Q1 2023

May 15, 2023

BUY
$2.65 - $3.81 $2.38 Million - $3.42 Million
898,596 Added 142.76%
1,528,050 $4.54 Million
Q4 2022

Feb 14, 2023

SELL
$3.38 - $4.22 $223,810 - $279,431
-66,216 Reduced 9.52%
629,454 $2.3 Million
Q3 2022

Nov 14, 2022

SELL
$3.43 - $5.83 $276,293 - $469,618
-80,552 Reduced 10.38%
695,670 $2.5 Million
Q2 2022

Oct 27, 2022

BUY
$4.41 - $5.69 $444,034 - $572,914
100,688 Added 14.9%
776,222 $4.11 Million
Q2 2022

Aug 15, 2022

BUY
$4.41 - $5.69 $444,034 - $572,914
100,688 Added 14.9%
776,222 $4.11 Million
Q1 2022

Oct 27, 2022

SELL
$4.81 - $6.99 $484,309 - $703,809
-100,688 Reduced 12.97%
675,534 $3.71 Million
Q1 2022

May 13, 2022

BUY
$4.81 - $6.99 $617,454 - $897,299
128,369 Added 23.46%
675,534 $3.71 Million
Q4 2021

Feb 14, 2022

SELL
$5.97 - $7.93 $386,151 - $512,928
-64,682 Reduced 10.57%
547,165 $3.73 Million
Q3 2021

Nov 15, 2021

BUY
$4.79 - $6.68 $2.93 Million - $4.09 Million
611,847 New
611,847 $3.73 Million

Others Institutions Holding CERS

About CERUS CORP


  • Ticker CERS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 177,090,000
  • Market Cap $317M
  • Description
  • Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended fo...
More about CERS
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.